Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company focused on therapies for liver and viral diseases, and its news flow reflects progress across this pipeline. Company announcements frequently highlight developments in chronic hepatitis B virus (HBV) programs, obesity and metabolic dysfunction-associated steatohepatitis (MASH) research, and broader corporate activities.
News items include updates on pevifoscorvir sodium, an oral capsid assembly modulator (CAM-E) under investigation for chronic HBV infection. Aligos issues press releases on clinical trial milestones, such as the initiation and enrollment of the Phase 2 B-SUPREME study, as well as data presentations at major scientific meetings. These communications describe antiviral activity, biomarker changes, and study designs that are central to understanding the company’s HBV strategy.
Investors and observers can also find coverage of ALG-055009, a THR-β agonist being studied for obesity and MASH. News from Aligos has detailed nonclinical in vivo results in diet-induced obese mouse models, showing synergistic body weight and fat mass loss when ALG-055009 is combined with incretin receptor agonists such as semaglutide or tirzepatide. Such updates provide insight into how the company positions this candidate within emerging combination approaches in cardiometabolic disease.
Beyond pipeline data, the ALGS news stream includes corporate and financial disclosures such as quarterly business updates, financial results, inducement grants under Nasdaq Listing Rule 5635(c)(4), amendments to equity plans, and senior leadership appointments. The company also announces participation in healthcare and investor conferences, where members of management discuss strategy and development programs.
By following ALGS news, readers can track clinical progress, preclinical findings, capital and governance actions, and organizational developments that shape Aligos Therapeutics’ efforts in liver and viral disease therapeutics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 11, 2023, Aligos Therapeutics (Nasdaq: ALGS) announced the presentation of seven posters at the EASL Congress 2023 in Vienna, occurring from June 21 to 24. The posters focus on five liver disease programs, showcasing data that highlights the company's advancements in addressing unmet medical needs in liver and viral diseases. Key presentations include data on Chronic Hepatitis B treatments involving compounds like CAM-E ALG-000184 and siRNA ALG-125755, as well as innovative approaches targeting Hepatocellular Carcinoma. Chairman & CEO Lawrence Blatt expressed optimism about these being potential best-in-class therapies. Detailed information will be made available on their corporate website post-conference.
Aligos Therapeutics (Nasdaq: ALGS) showcased positive results for its thyroid receptor-beta agonist candidate, ALG-055009, during the 15th Paris Hepatology Conference from March 27-29, 2023. The Phase 1 data revealed a favorable safety and pharmacokinetic profile in healthy volunteers and subjects with hyperlipidemia. The study demonstrated low variability and similar bioavailability for both liquid and gelcap formulations, which are set for a Phase 2 study with a regulatory filing anticipated in Q4 2023. These results indicate promising potential for addressing unmet medical needs in liver and viral diseases.
Aligos Therapeutics (Nasdaq: ALGS) announced significant advancements in its drug development pipeline for NASH, COVID-19, and CHB diseases, highlighting progress in clinical trials and positive data from candidate ALG-055009. The company reported a cash balance of $125.8 million as of December 31, 2022, down from $205.8 million in 2021, but sufficient to fund operations through the end of 2024. Net losses decreased to $21.9 million for Q4 2022, compared to $37.7 million in Q4 2021, and annual losses were $96.0 million, down from $128.3 million.
The firm anticipates key data readouts throughout 2023, which could drive shareholder value.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced it will report its fourth quarter 2022 financial results on March 9, 2023, after U.S. market close. The company specializes in developing therapeutics targeting nonalcoholic steatohepatitis (NASH) and viral diseases, aiming to be a leader in liver disease treatment. Founded in 2018, Aligos is focusing on advancing its pipeline of potentially best-in-class molecules. The press release includes forward-looking statements, highlighting risks such as drug development uncertainties and capital resource sufficiency.